期刊文献+

抗新生血管生成药(贝伐单抗)治疗翼状胬肉的研究现状 被引量:5

Research Status of Anti-vascular Endothelial Growth Factors( Bevacizumab) Treating Pterygia
下载PDF
导出
摘要 翼状胬肉是鼻侧球结膜下的纤维组织肥厚增生呈翼状侵入角膜的一种疾病,目前缺乏统一的治疗方法。最近研究发现,血管内皮生长因子(VEGF)引导的新生血管形成在翼状胬肉发病机制中占主导地位。抗VEGF药物具有抑制新生血管、减少渗出的作用,被广泛应用于以新生血管再生为特点的眼后段疾病,同时也为翼状胬肉提供了新的治疗手段。 Pterygia is characterized by the encroachment of a fleshy fibrovascular tissue from the bulbar conjunctiva into the cornea, but the treatment is presently uncertain. Recently, many papers suggest VEGF inducing angiogenesis playes an important role in the patbogenesis of pterygia. Anti-angiogenesis agents with the function of angiogenesis inhibition and exudation reduction have mainly been widely used in the posterior segment ocular diseases characterized by neovascularization, which also provides a new treatment for pterygia.
作者 张蒙 陈子林
出处 《医学综述》 2014年第1期109-111,共3页 Medical Recapitulate
关键词 抗血管新生药 贝伐单抗 翼状胬肉 Anti-angiogenesis agents Bvaclzumab Pterygia
  • 相关文献

参考文献19

  • 1魏文斌,莫静.谨慎开展、科学评价抗新生血管生成类药物治疗脉络膜新生血管[J].中华眼科杂志,2008,44(3):193-195. 被引量:3
  • 2屠颖,魏文斌.抗新生血管生成药眼科的临床应用bevacizumab(Avastin)在眼科的临床应用[J].国际眼科纵览,2007,31(3):201-205. 被引量:3
  • 3Scholl S, Kirehhof J, Augustin AJ. Antivaseular endothelial growth factors in anterior segment diseases[ J]. 2010,46 : 133-139.
  • 4Park CY, Choi JS, Lee S J, et al. Cyclooxygenase-2-expressing mac- rophages in human pterygium co-express vascular endothelial growth factor[ J]. Mol Vis,2011,17:3468-3480.
  • 5Khalfaoui T, Mkannez G, Colin D, et al. Immunohistochemical analysis of vascular endothelial growth factor ( VEGF ) and p53 expression in pterygium from Tunisian patients [ J ]. Pathol Biol (Paris) ,2011,59(3) :137-141.
  • 6Livezeanu C, Cr~ii~oiu MM, M~ineseu R, et al. Angiogenesis in the pathogenesis of pterygium [ J ]. Rom J Morphol Embryol, 2011,52 (3) :837-844.
  • 7Marcovich AL, Morad Y, Sandbank J,et al. Angiogenesis in pteryg- ium: morphometric and immunohistochemical study [ J ]. Curt Eye Res ,2002,25 ( 1 ) : 17-22.
  • 8张雷,于晓艳,丛璐.VEGF在翼状胬肉组织中的表达[J].中国实验诊断学,2006,10(12):1464-1465. 被引量:5
  • 9Lee DH, Cho H J, Kim JT, et al. Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia [ J ]. Cornea,2001,20(7 ) :738-742.
  • 10Hosseini H, Nejabat M, Khalili MR. Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia [ J ]. Med Hypotheses, 2007,69 ( 4 ) : 925-927.

二级参考文献16

  • 1朱雅琴,姚克.翼状胬肉发病机制研究进展[J].国外医学(眼科学分册),2005,29(3):163-166. 被引量:59
  • 2李琳,周希瑗.VEGF和PEDF对眼底新生血管的共同调节作用[J].国外医学(临床生物化学与检验学分册),2005,26(11):819-821. 被引量:4
  • 3VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group. Pegaptanib sodium for neovascular age-related macular degeneration : two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology, 2006,113:992-1001.
  • 4MARINA Study Group. Ranibizumb for neovascular age-related macular degeneration. N Engl J Med, 2006,355:1419-1431.
  • 5ANCHOR Study Group. Ranibizumb vs verteporfin for neovascular age-related macular degeneration. N Engl J Med, 2006, 355: 1432-1444.
  • 6Avery RL Intravitreal bevacizumb (Avasfin) for neovascular agerelated maollar degeneration. Ophthalmology,2006,113:363-372.
  • 7Carvounis PE. Retinal pigment epithelium tear following ranibizumab for exudative age-related macular degeneration. Am J Ophthalmol, 2007,143:504-505.
  • 8Bakri SJ. Retinal pigment epithelium tear after intravitreal ranibizumab. Am J Ophthalmol, 2007,143:505-507.
  • 9Fung AE. An optical coherence tomography-guided, variable dose regimen with intravitreal ranibizumb (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol, 2007,143 : 566-583.
  • 10FOCUS Study Group. Ranibizumab combined with verteporfin therapy in neovascular age-related macular degeneration. Year one result of FOCUS Study. Arch Ophthalmol, 2006,124 : 1532-1542.

共引文献7

同被引文献65

引证文献5

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部